Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

RAS/RAF landscape in monoclonal plasma cell conditions

Blood (2024) 144 (2): 201–205.

https://doi.org/10.1182/blood.2023022295

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Blood (2023) 142 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2023-188896

Published: 2023

Journal Articles

Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status in Anti-CD38-Naïve Population

Xavier Leleu, Jean Fontan, Aurore Perrot, Lionel Karlin, Cyrille Touzeau, Samantha Schulmann, Salomon Manier, Karim Belhadj Merzoug, Adrien Trebouet, Patricia Zunic, Jean Marc Schiano De Colella, Christina Tekle, Marianne Gaucher, Olivier Decaux

Blood (2023) 142 (Supplement 1): 7419.

https://doi.org/10.1182/blood-2023-179532

Published: 2023

Journal Articles

Allogeneic Transplant As a Curative Option for Relapsed/Refractory Large B-Cell Lymphoma in the Era of CAR T-Cell Therapy: A Monocentric Retrospective Study

Pauline Roché, Gabriel Brisou, Sabine Furst, Robin Noel, Catalina Montes De Oca, Aude Collignon, Luca Inchiappa, Jean Marc Schiano De Colella, Isabelle Brenot Rossi, Thibaut Reichert, Sophie Thévenet, Bechara Mfarrej, Boris Calmels, Didier Blaise, Christian Chabannon, Raynier Devillier

Blood (2022) 140 (Supplement 1): 7740–7741.

https://doi.org/10.1182/blood-2022-157915

Published: 2022

Journal Articles

ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells

Florent Amatore, Nicolas Ortonne, Marc Lopez, Mathilde Barré, Florence Orlanducci, Remy Castellano, Saskia Ingen-Housz-Oro, Amandine De Croos, Laurent Gorvel, Armelle Goubard, Reda Bouabdallah, Jean Marc Schiano De Colella, Jean-Jacques Grob, Philippe Gaulard, Martine Bagot, Armand Bensussan, Emmanuel Delaporte, Daniel Olive

Blood (2021) 138 (Supplement 1): 790.

https://doi.org/10.1182/blood-2021-150677

Published: 2021

Journal Articles

Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance

Blood (2021) 138 (Supplement 1): 2417.

https://doi.org/10.1182/blood-2021-148218

Published: 2021

Journal Articles

Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy

Blood (2021) 138 (Supplement 1): 1387.

https://doi.org/10.1182/blood-2021-150478

Published: 2021

Journal Articles

Salvage Therapy with Brentuximab-Vedotin and Bendamustine for Patients with Relapsed/Refractory T Cell Lymphoma. a Multicenter and Retrospective Study

Blood (2021) 138 (Supplement 1): 620.

https://doi.org/10.1182/blood-2021-150953

Published: 2021

Journal Articles

Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort

Reid W Merryman, MD, Luca Castagna, MD, Paolo Corradini, MD, Vincent T. Ho, MD, David A. Bond, MD, Samantha Jaglowski, MDMPH, Michael A Spinner, Sally Arai, MD, Robert Lowsky, MD, Alex F. Herrera, MD, Anna Guidetti, MD, Geoffrey Shouse, DO, PhD, Didier Blaise, MD PhD, Jean Marc Schiano De Colella, MD, Talha Badar, MD, Mehdi Hamadani, MD, Stephen M Ansell, MD PhD, Yago Nieto, MD PhD, Chloe Spilleboudt, MD, Tatyana A. Feldman, MD, Lori Dahncke, BSN, Anurag K. Singh, MD, Joseph P. McGuirk, DO, Mohamad Mohty, MD PhD, Remy Dulery, MD, Aspasia Stamatoulas Bastard, Roch Houot, MD PhD, Guillaume Manson, MD, Marie-Pierre Moles, MD, Corentin Orvain, MD, Kamal Bouabdallah, MD, Matthew J. Frigault, MD, Yi-Bin Chen, Ryan C. Lynch, MD, Stephen D. Smith, MD, Uttam Rao, MD, Michael T Byrne, DO, Jason Romancik, MD, Jonathon B. Cohen, MDMS, Robin M. Joyce, MD, Maryam Rahimian, MD, Asad Bashey, MD PhD, Hatcher J. Ballard, BS, Jakub Svoboda, MD, Laura Giordano, Valter Torri, Beatrice Casadei, MD, Martina Sollini, MD, Chiara De Philippis, MD, Massimo Magagnoli, MD, Armando Santoro, Philippe Armand, MD PhD, Pier Luigi Zinzani, MD PhD, Carmelo Carlo-Stella, MD

Blood (2019) 134 (Supplement_1): 775.

https://doi.org/10.1182/blood-2019-125039

Published: 2019

Journal Articles

Haploidentical Stem Cell Transplantation for Patients Relapsing after First Allogeneic Transplantation

Virginie Lavoipierre, Samia Harbi, MD, Luca Castagna, MD, Angela Granata, MD, Sabine Fürst, MD, Catherine Faucher, MD, Faezeh Legrand, Stefania Bramanti, MD, Christian Chabannon, MD PhD, Norbert Vey, MD PhD, Jérome Rey, Reda Bouabdallah, MD, Jean Marc Schiano De Colella, Djamel Mokart, Pierre-Jean Weiller, Prof., Didier Blaise, MD PhD, Raynier Devillier, MD PhD

Blood (2016) 128 (22): 4618.

https://doi.org/10.1182/blood.V128.22.4618.4618

Published: 2016

Journal Articles

Allogeneic Hematopoietic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with High Risk Multiple Myeloma: Comparative Analysis of Outcomes Between Unrelated and Related Donor

Jean El-Cheikh, MD PhD, Sabine Furst, MD, Anne Marie Stoppa, Roberto Crocchiolo, MD, Catherine Faucher, MD, Luca Castagna, MD, Angela Granata, Claire Oudin, Patrick Ladaique, Boris Calmels, Claude Lemarie, jean Marc schiano De Colella, Christian Chabannon, MD, PhD, Didier Blaise, MD

Blood (2011) 118 (21): 4513.

https://doi.org/10.1182/blood.V118.21.4513.4513

Published: 2011

Journal Articles

Diffuse Large B-Cell Lymphoma in the Elderly: Outcome of Patients From a Single Center

Jean-Marc Schiano de Colella, MD, Diane Coso, MD, Benjamin Esterni, Ph.D., Anne-Marie Stoppa, Vadim Ivanov, MD, PhD, Thérèse Aurran, MD, Florence Broussais, MD, Jerome Rey, MD, Frederique Rousseau, MD, Maud Cecile, MD, Didier Blaise, MD, Reda Bouabdallah, MD

Blood (2011) 118 (21): 2693.

https://doi.org/10.1182/blood.V118.21.2693.2693

Published: 2011

Journal Articles

Lenalidomide Followed with Donor Lymphocytes Infusion (DLI) After Allogeneic Stem-Cell Transplantation (Allo-SCT) with Reduced-Intensity Conditioning in Patients with High Risk Multiple Myeloma

Jean El-Cheikh, MD PhD, Roberto Crocchiolo, MD, Patrick Ladaique, Sabine Furst, MD, Luca Castagna, MD, Catherine Faucher, MD, Angela Granata, Claire Oudin, Claude Lemarie, Boris Calmels, Anne Marie Stoppa, jean Marc schiano De Colella, Segolene Duran, Christian Chabannon, MD, PhD, Didier Blaise, MD

Blood (2011) 118 (21): 4310.

https://doi.org/10.1182/blood.V118.21.4310.4310

Published: 2011

Journal Articles

Impact of the New Anti-Myeloma Drugs on Outcome of Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with High-Risk Multiple Myeloma

Jean El-Cheikh, MD PhD, Roberto Crocchiolo, MD, Jean Marie Boher, PhD, Sabine Furst, MD, Anne Marie Stoppa, Catherine Faucher, MD, Luca Castagna, MD, Angela Granata, Claire Oudin, jean Marc schiano De Colella, Diane Coso, MD, Reda Bouabdallah, MD, Didier Blaise, MD

Blood (2011) 118 (21): 4456.

https://doi.org/10.1182/blood.V118.21.4456.4456

Published: 2011

Journal Articles

Potential Synergic Effect of Lenalidomide-Rituximab Combination: Durable Complete Remissions in Refractory Diffuse Large B Cell Lymphoma

Vadim Ivanov, MD, PhD, Diane Coso, MD, Therese Aurran-Schleinitz, MD, Jean-Marc Schiano de Colella, MD, Anne-Marie Stoppa, MD, Jerome Rey, MD, Florence Broussais, MD, Didier Blaise, MD, Reda Bouabdallah, MD

Blood (2011) 118 (21): 4989.

https://doi.org/10.1182/blood.V118.21.4989.4989

Published: 2011

Journal Articles

Frontline High Dose Chemotherapy Supported by Autologous PBSCT Might Improve Survival In Elderly Patients (≥60 Years) with High Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Vadim Ivanov, MD, Diane Coso, MD, Jerome Rey, MD, Therese Aurran-Schleinitz, MD, Anne-Marie Stoppa, MD, Jean-Marc Schiano de Colella, MD, Didier Blaise, MD, Reda Bouabdallah, MD

Blood (2010) 116 (21): 5190.

https://doi.org/10.1182/blood.V116.21.5190.5190

Published: 2010

NARROW

RAS/RAF landscape in monoclonal plasma cell conditions

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status in Anti-CD38-Naïve Population

Allogeneic Transplant As a Curative Option for Relapsed/Refractory Large B-Cell Lymphoma in the Era of CAR T-Cell Therapy: A Monocentric Retrospective Study

ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells

Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance

Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy

Salvage Therapy with Brentuximab-Vedotin and Bendamustine for Patients with Relapsed/Refractory T Cell Lymphoma. a Multicenter and Retrospective Study

Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort

Haploidentical Stem Cell Transplantation for Patients Relapsing after First Allogeneic Transplantation

Allogeneic Hematopoietic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with High Risk Multiple Myeloma: Comparative Analysis of Outcomes Between Unrelated and Related Donor

Diffuse Large B-Cell Lymphoma in the Elderly: Outcome of Patients From a Single Center

Lenalidomide Followed with Donor Lymphocytes Infusion (DLI) After Allogeneic Stem-Cell Transplantation (Allo-SCT) with Reduced-Intensity Conditioning in Patients with High Risk Multiple Myeloma

Impact of the New Anti-Myeloma Drugs on Outcome of Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with High-Risk Multiple Myeloma

Potential Synergic Effect of Lenalidomide-Rituximab Combination: Durable Complete Remissions in Refractory Diffuse Large B Cell Lymphoma

Frontline High Dose Chemotherapy Supported by Autologous PBSCT Might Improve Survival In Elderly Patients (≥60 Years) with High Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only